Ro AI Visibility Market Strategy Report - ED Treatment Pills

Answer Capsule

Ro holds the second-strongest recommendation position in the October 2026 ED Treatment Pills benchmark, with 55.07% valid recommendation coverage across 296 qualified observations. The brand is visible in 82.43% of qualified observations and converts that presence into valid recommendations at a strong rate, but it trails category leader Hims on nearly every recommendation-stage metric. Ro's clearest win is its top-three placement rate of 42.23%, which nearly doubled from its July baseline. Its clearest weakness is first-position conversion: Ro is the rank-one recommendation in only 9.80% of observations, less than half of Hims at 28.38%. The clearest opportunity sits in closing the rank-one gap on discovery and evaluation prompts where Ro is already shortlisted but not selected first.

Who This Report Is For

This report is for Ro's marketing, growth, and brand strategy teams, and for category analysts tracking how ED treatment brands are recommended across AI platforms during the discovery and consideration stage of the buyer journey.

Report Card

Executive Summary

Ro enters October 2026 as the second most recommended ED treatment brand in the benchmark, with 55.07% valid recommendation coverage across 296 qualified observations. That places Ro 5.74 percentage points behind Hims at 60.81% and 4.06 points ahead of GoodRx Care at 51.01%. The brand's raw mention presence rate of 82.43% confirms that Ro is consistently surfaced in AI-generated answers, but presence alone does not capture how often the brand is actually recommended or how prominently it appears.

The recommendation-stage picture is stronger than the presence picture. Ro recorded 163 valid recommendations, 125 top-three placements, and 29 rank-one placements in October 2026. Its top-three rate of 42.23% is the second highest in the category, behind only Hims at 48.65%. That placement profile shows Ro is routinely included in AI-generated shortlists for ED treatment options.

The gap to Hims is concentrated in first-position recommendations. Ro's rank-one rate of 9.80% is less than half of Hims at 28.38%, even though the two brands hold relatively close coverage at 55.07% and 60.81%. This means Ro is frequently shortlisted but rarely selected as the single best option. The benchmark's placement snapshot confirms that close coverage can still hide substantially different first-position rates.

Ro's strongest platform signal comes from AI Overviews, where it holds 66.10% valid recommendation coverage and a 51.69% top-three rate across 118 observations. Google AI Mode is the second-strongest platform at 62.96% coverage and a 55.56% top-three rate. These two Google surfaces carry the largest observation volumes in the benchmark and represent Ro's most reliable recommendation environment.

The weakest platform signal is Copilot, where Ro holds only 30.77% valid recommendation coverage across 26 observations, with a rank-one rate of 3.85%. Perplexity shows a similar pattern at 43.75% coverage across 16 observations. Both platforms represent smaller observation volumes, but the coverage gap relative to AI Overviews and AI Mode is material.

The strongest cluster is C01, Best ED Treatment Pills Discovery and Evaluation, which carries all 296 qualified observations in the October benchmark. The pricing and value cluster and the multi-brand comparison cluster both recorded zero qualified observations, so the current public series cannot speak to how Ro performs on cost, affordability, or head-to-head comparison prompts.

Ro's net sentiment score of 0.8074 reflects strongly positive framing across its 244 mentions, with 197 positive, 47 neutral, and zero negative classifications. That sentiment profile is consistent with the category's overall positive framing environment and does not indicate any cautionary or negative narrative risk in the current data.

What Ro Is Winning

Questions This Section Answers

• Where does Ro rank in ED Treatment Pills recommendation coverage, and which brands does it beat?
• How much did Ro's top-three placement and rank-one rates improve from the July 2026 baseline?
• Which AI platform gives Ro its strongest recommendation coverage and top-three rate?

Ro holds the second-strongest recommendation position in the ED Treatment Pills category. Its 55.07% valid recommendation coverage places it ahead of GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum. Only Hims records higher coverage.

The brand's top-three placement rate of 42.23% is a genuine strength. Ro appears among the first three recommended options in 125 of 296 qualified observations, the second-highest count in the category. This placement rate rose 11.4 percentage points from its July 2026 baseline of 30.8%, a significant improvement that shows Ro is converting visibility into shortlist inclusion at a higher rate than it did at the start of the measurement series.

Ro's rank-one rate also improved from baseline. At 9.80% in October 2026, it is up 5.5 percentage points from 4.3% in July 2026. While this remains well below Hims, the directional movement shows progress in first-position conversion.

The brand's strongest platform is AI Overviews, where Ro holds 66.10% valid recommendation coverage and a 51.69% top-three rate across 118 observations. Ro's presence rate on AI Overviews is 85.59%, and its rank-one rate on that platform is 5.93%. AI Overviews carries the largest observation volume in the benchmark and represents Ro's most consistent recommendation environment.

Ro's net sentiment score of 0.8074 is positive and consistent with the category's framing environment. The brand recorded zero negative mentions across 244 classified mentions, which means no cautionary or negative narrative is present in the current data.

Where Ro Has the Clearest AI Visibility Gaps

Questions This Section Answers

• How large is Ro's first-position recommendation gap compared to Hims?
• On which platforms is Ro's rank-one rate weakest?
• What does Ro's presence decline alongside placement improvement suggest about its prompt coverage?

The clearest gap is first-position recommendation conversion. Ro is the rank-one recommendation in only 9.80% of qualified observations, compared to 28.38% for Hims. That 18.58 percentage point gap is the single largest recommendation-stage difference between the two leading brands. Ro is being shortlisted at a rate close to Hims, but it is not being selected as the single best option at anywhere near the same frequency.

The platform-level picture shows where this gap is widest. On Copilot, Ro holds a rank-one rate of 3.85% across 26 observations, with valid recommendation coverage of 30.77%. On Perplexity, Ro holds a rank-one rate of 12.50% across 16 observations, with coverage of 43.75%. These platforms carry smaller observation volumes than AI Overviews and AI Mode, but the coverage and placement gaps are material.

Ro's presence rate slipped 4.7 percentage points from its July baseline, from 87.1% to 82.4%. The brand is being named slightly less often in AI-generated answers, even as its recommendation placement improved. This pattern, where presence declines while placement rises, suggests Ro is being mentioned in fewer but more recommendation-focused contexts. The benchmark flags this as the inverse of a visibility-led decline, but it also raises the question of whether Ro is dropping out of certain prompt types entirely.

The cluster picture is limited by data availability. All 296 qualified observations in October 2026 fell into the brand recommendation cluster. The pricing and value cluster and the multi-brand comparison cluster recorded zero qualified observations, so the benchmark cannot currently show how Ro performs on cost, affordability, or direct head-to-head comparison prompts. Those commercial questions remain outside the scope of what the October data can characterize.

The competitor displacement picture is clear at the top. Hims holds the category lead with 60.81% coverage, 48.65% top-three rate, and 28.38% rank-one rate. GoodRx Care is the strongest challenger on placement improvement, with a 35.47% top-three rate and a 15.88% rank-one rate, both up sharply from July. Ro sits between these two brands on coverage but trails GoodRx Care on rank-one rate, which means Ro is being selected first less often than a brand with lower overall coverage.

Biggest Opportunity

Questions This Section Answers

• Which prompt types represent the highest-value opportunity to convert Ro's top-three placements into first-position recommendations?
• What evidence and framing does Ro need to strengthen to move from a shortlisted option to the recommended first choice?

Ro's biggest opportunity is closing the rank-one gap on discovery and evaluation prompts where the brand is already shortlisted but not selected first. The benchmark shows Ro appears in the top three in 42.23% of qualified observations but is the first recommendation in only 9.80%. That means roughly 32 percentage points of top-three placements are not converting to first position.

The highest-value prompt types for this opportunity are the discovery and evaluation questions that make up the C01 cluster, such as "What is the best generic Viagra?" and "Which online doctors are legit?" These prompts ask for a single best option or a trusted provider, and they represent the moment where a shortlist mention becomes a first-choice recommendation. Ro's strong presence on AI Overviews and AI Mode means the brand is already being retrieved and considered on these surfaces. The opportunity is to strengthen the evidence and framing that moves Ro from a listed option to the recommended first choice.

Competitive Landscape

Questions This Section Answers

• How does Ro compare to Hims and GoodRx Care on top-three rate, rank-one rate, and average recommended rank?
• Why does Ro's rank-one rate trail GoodRx Care despite higher overall coverage?

Hims holds the strongest recommendation-stage position in the ED Treatment Pills category, with Ro as the closest challenger and GoodRx Care as the fastest-improving brand on placement. The table below shows how the tracked brands compare on top-three rate, rank-one rate, average recommended rank, and net sentiment.

Average recommended rank covers rank-eligible recommendations only.

Ro's position in the table shows a brand with strong shortlist inclusion but weaker first-position conversion. Its top-three rate of 42.23% is second only to Hims, but its rank-one rate of 9.80% places it third, behind both Hims and GoodRx Care. Ro's average recommended rank of 2.4702 is second-best in the category, which means when Ro is recommended, it tends to appear near the top of the list. The gap is not about being buried in long lists; it is about not being selected first often enough.

Prompt Evidence

AI Overviews / Brand Recommendation Prompt: "What is the best generic Viagra?" Result: Ro appeared in the recommendation set with a top-three placement, contributing to its 51.69% top-three rate on AI Overviews.

Google AI Mode / Brand Recommendation Prompt: "Which online doctors are legit?" Result: Ro was included in the shortlist with a top-three placement, consistent with its 55.56% top-three rate on AI Mode.

Copilot / Brand Recommendation Prompt: "What is the best online prescription?" Result: Ro received a valid recommendation but did not appear in the top three, reflecting the platform's lower placement rate for the brand.

Perplexity / Brand Recommendation Prompt: "How much does it cost to see a virtual doctor?" Result: Ro appeared in the recommendation set with a rank-one placement on this prompt, one of the brand's 29 first-position recommendations in October.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map Ro's prompt-level recommendation patterns across all six AI platforms to identify exactly which discovery and evaluation prompts produce top-three placements versus first-position recommendations.

Phase 2: Recommendation Readiness Plan Prioritize the prompts where Ro is shortlisted but not selected first, and define the evidence, framing, and source signals needed to move those placements to rank one.

Phase 3: Owned Answer Layer Buildout Strengthen Ro's owned content on the specific question themes where the brand is being retrieved but not recommended first, with clear, extractable answers that AI systems can synthesize.

Phase 4: Citation and Authority Layer Development Expand the public evidence layer that supports Ro's recommendation position, focusing on the source types and domains that AI systems cite when forming ED treatment recommendations.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track Ro's coverage, top-three rate, rank-one rate, and sentiment month over month to measure whether the rank-one gap is closing and where competitor displacement is occurring.

Why This Matters

AI presence alone is not enough. Ro is visible in 82.43% of qualified observations, but it is the first recommendation in only 9.80%. That gap between being mentioned and being selected first is where buyer decisions are shaped. A brand that appears in every shortlist but is never the top choice is losing the recommendation moment to competitors who are selected first.

The next move is targeted correction of the prompt, page, and citation layers that drive first-position recommendations. Ro's strong top-three rate and average recommended rank show the brand is already in the consideration set. The opportunity is to convert that consideration into selection by strengthening the specific evidence and framing that AI systems use when deciding which ED treatment brand to recommend first.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Ro in October 2026: (197 × 1 + 47 × 0 + 0 × -1) / 244 = 0.8074

This score matters because unclassified mention counts are misleading. A brand can appear in hundreds of AI responses without being recommended, and a neutral reference is not the same as a positive recommendation. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal in commercial value.

Counting all mentions as wins is bad measurement. Ro's 244 mentions include 197 positive classifications and 47 neutral classifications. The 47 neutral mentions represent contexts where Ro was referenced but not framed as a recommended option. Classified sentiment is required before interpreting AI visibility, because it separates the mentions that carry recommendation weight from those that do not.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Ro's AI recommendation performance in the ED Treatment Pills category for October 2026. It is not a client implementation case study and does not imply that any remediation work has been performed.
2. The reporting window is October 2026. The benchmark series began in July 2026, and month-over-month comparisons reference that baseline where available.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode. All six registered qualified observations in October 2026.
4. The October run began with 800 prompt-surface observations. After qualification, 296 observations were eligible for brand-level metrics. The public percentages use the 296 qualified observations as the denominator, not the raw collection.
5. The competitor universe includes 10 tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum.
6. Three public high-intent clusters were defined: C01 Best ED Treatment Pills Discovery and Evaluation, C02 ED Treatment Pills Comparison Brand and Drug Matchups, and C03 ED Treatment Pills Pricing Cost and Affordability. Only C01 recorded qualified observations in October 2026.
7. Stage 0 extraction captures the query, AI platform, answer, brand outcome, recommendation placement, sentiment, and citations where exposed. Source presence is evidence about the information environment and is not automatically proof of causation.
8. A mention is counted when Ro appears in an AI-generated response to a qualified prompt, regardless of recommendation status. Ro recorded 244 mentions in October 2026.
9. A valid recommendation is counted when Ro appears in a recommendation context that the dataset marks as valid. Ro recorded 163 valid recommendations in October 2026.
10. Top-three rate is the share of qualified observations where Ro appears among the first three recommended options. Rank-one rate is the share where Ro is the single first recommended option.
11. Average recommended rank covers rank-eligible recommendations only. Ro's average recommended rank of 2.4702 reflects its position when it receives valid rank credit.
12. Limitations: The October benchmark contains no qualified observations in the pricing and value or multi-brand comparison clusters, so this report cannot characterize Ro's performance on cost, affordability, or head-to-head comparison prompts. The PlushCare and plushcare entries are the same commercial entity under two tracked casings and should be read together. Small-count brands such as K Health, Optum, and Blink Health carry limited weight in percentage comparisons.

See How AI Is Recommending Your Brand

The public benchmark shows where Ro stands in AI-generated recommendations for ED treatment pills. A company-level AI visibility audit maps the prompt, platform, competitor, and citation patterns behind those numbers into a prioritized strategy. It answers the question of which prompts Ro should win next and what evidence will move the recommendation outcome.